Skip to main content
Livermore
Livermore
ZHEN

Lipocine Inc.

LPCN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001535955

In the last 90 days, Lipocine Inc. insiders filed 1 open-market purchase and 0 sales; 36 institutions reported holding it in 13F filings for Q2 2026, worth $7.63M in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding Lipocine Inc. changed between Q4 2025 and Q1 2026.

All holders in Q1 2026All holders in Q4 2025

13F holders of LPCN: Q4 2025 compared with Q1 2026
MeasureQ4 2025Of which not filed for Q1 2026Q1 2026Change
Holders26147+22
Shares1.63M221.9K3.12M+1.71M (+121.5%)
Value$13.1M$1.78M$24.9M+$13.6M (+120.3%)

1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (24)

Institutions that held Lipocine Inc. at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to LPCN in Q1 2026
InstitutionSharesValue% of portfolio
Eversept Partners, LP294,989$2.36M0.16%
Rosalind Advisors, Inc.221,616$1.77M0.73%
Vanguard Capital Management LLC200,668$1.60M0.00%
AIGH Capital Management LLC200,000$1.60M0.33%
StemPoint Capital LP160,420$1.28M0.25%
Seven Fleet Capital Management LP124,942$998.3K0.31%
Birchview Capital, LP111,786$893.2K0.51%
Mink Brook Asset Management LLC66,812$533.8K0.30%
Exome Asset Management LLC60,861$486.3K0.29%
J. Goldman & Co LP42,170$336.9K0.02%
Two Sigma Investments, LP33,750$269.7K0.00%
Vanguard Fiduciary Trust Co32,413$259.0K0.00%
Citadel Advisors LLC29,088$232.4K0.00%
ADAR1 Capital Management, LLC23,180$185.2K0.01%
XTX Topco Ltd17,923$143.2K0.00%
Prelude Capital Management, LLC12,630$100.9K0.01%
Barclays PLC9,412$75.2K0.00%
Wells Fargo & Company2,706$21.6K0.00%
Vanguard Global Advisers, LLC1,691$13.5K0.00%
Tower Research Capital LLC (TRC)933$7.46K0.00%
JPMorgan Chase & Co392$2.97K0.00%
PlanVest Financial, Inc111$8870.00%
Bogart Wealth, LLC3$240.00%
Farther Finance Advisors, LLC1$90.00%

Sold out (2)

Institutions that held Lipocine Inc. at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of LPCN in Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
HighMark Wealth Management LLC100$803
Bank of America Corp52$417

Not filed for Q1 2026 yet (1)

Institutions that held Lipocine Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding LPCN in Q4 2025 that haven't filed for Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Vanguard Group Inc221,867$1.78M